Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Tokyo Joe's Cafe / Anything goes -- Ignore unavailable to you. Want to Upgrade?

To: musicguy who wrote (19716)	5/20/1998 1:50:00 PM
From: MoneyMade	Respond to of 34592

GREAT NEWS HYALF.... MISSISSAUGA, Ont., May 20 /CNW-PRN/ - Hyal Pharmaceutical Corporation (NASDAQ/NNM:HYALF; TSE:HPC) announced today that its lead product, Solarase, has received approval from the Therapeutic Products Directorate of Health Canada (formerly HPB) for marketing in Canada. The product is a topical gel formulation to treat actinic keratosis (AK), precancerous skin lesions caused by exposure to the sun. ''It is very exciting because Solarase is the first topical NSAID to be approved anywhere in North America. This approval endorses the extensive and high quality research and development that Hyal has conducted in this area. This new mode of therapy for actinic keratosis further validates the viability of Hyal's HIT(TM) technology.'' said Dr. Zenas B. Noon, Jr., Hyal's President and CEO. This approval is important and timely, closely following Canada's Sun Awareness Week, May 11 - 17. The medical community and general public are becoming increasingly aware of the dangers of excessive sun exposure. Dr. Jason Rivers, former National Director of the Canadian Dermatology Association's Sun Awareness Program, speaking from the University of British Columbia, stated ''I expect that Solarase will be a very useful addition in the treatment of actinic keratosis. It will help patients reduce the often painful and cosmetically distressing side effects of other therapies.'' AK is a common precancerous skin lesion caused by overexposure to sunlight. A small number of these lesions will develop into squamus cell carcinoma, a malignant skin disease. According to The Skin Cancer Foundation of the United States, AK affects one in six people worldwide. With approximately four million treatments annually, AK represents a potential US$240 million market in the U.S. alone. Hyal expects to file a submission to the FDA in the third quarter seeking approval to market Solarase in the United States. Along with the recent approvals in Germany, Sweden, Italy, France and the United Kingdom, the Canadian approval should further enhance the attractiveness of Solarase to potential licensees and merger or acquisition partners. Solarase utilizes Hyal's patented HIT technology which targets and retains drugs in areas of dermal pathology. The benefits to the patient are minimal systemic drug absorption and outstanding safety. Hyal Pharmaceutical Corporation is a drug delivery development company engaged in research and development utilizing its propriety Hyaluronan Induced Targeting (HIT) Technology and Hyaluronan Improved Liposome (HILT) Technology(TM). The Company's strategy is to commercialize its developments by outlicensing on a global basis. This news release may contain forward-looking statements relating to the future performance of Hyal. Forward-looking statements, specifically those concerning future performance, are subject to certain risks and uncertainties, and actual results may differ materially. These risks and uncertainties are detailed from time to time in the Company's filings with the appropriate securities commissions. %SEDAR: 00003081E SOURCE Hyal Pharmaceutical Corporation /CONTACT: Michael A. Byrne, Vice President Finance, (905) 625-8181/ (HPC. HYALF)